MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Sanofi

Suletud

54.37 -2

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

54.32

Max

55.44

Põhinäitajad

By Trading Economics

Sissetulek

-2.3B

499M

Müük

-6.5B

7.6B

P/E

Sektori keskmine

23.205

63.778

Aktsiakasum

0.682

Dividenditootlus

3.67

Kasumimarginaal

6.539

Töötajad

82,878

EBITDA

-3.7B

563M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+16.75% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.67%

2.39%

Turustatistika

By TradingEconomics

Turukapital

-1.5B

136B

Eelmine avamishind

56.37

Eelmine sulgemishind

54.37

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Sanofi Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. märts 2025, 06:43 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

3. veebr 2025, 13:19 UTC

Omandamised, ülevõtmised, äriostud

L'Oreal to Sell $3.1 Billion Stake in Sanofi Back to Pharma Group -- Update

3. veebr 2025, 09:31 UTC

Omandamised, ülevõtmised, äriostud

Correction to L'Oreal article

3. veebr 2025, 07:09 UTC

Omandamised, ülevõtmised, äriostud

L'Oreal Agrees to Sell Back 2.3% Stake in Sanofi for $3.1 Billion

30. jaan 2025, 11:09 UTC

Tulu

Correction to Sanofi Article

30. jaan 2025, 06:47 UTC

Tulu

Sanofi Issues $5.2 Billion Share Buyback; Expects Sales, Core Earnings Growth

20. märts 2025, 06:05 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20. märts 2025, 06:05 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20. märts 2025, 06:04 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Pay $600M Upfront

20. märts 2025, 06:02 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20. märts 2025, 06:00 UTC

Omandamised, ülevõtmised, äriostud

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

19. veebr 2025, 06:35 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Transaction Remains Subject to Obtaining Customary Regulatory Approvals

19. veebr 2025, 06:34 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Closing Is Expected to Take Place in 2Q at the Earliest

19. veebr 2025, 06:34 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Terms of Transaction Remain Unchanged From Those Previously Disclosed

19. veebr 2025, 06:33 UTC

Omandamised, ülevõtmised, äriostud

Sanofi to Remain Significant Shareholder in Opella Consumer Business

19. veebr 2025, 06:33 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: Bpifrance to Participate as Minority Shareholder With 2% Stake in Opella

19. veebr 2025, 06:33 UTC

Omandamised, ülevõtmised, äriostud

Sanofi: This Follows Completion of Required Social and Corporate Procedures

19. veebr 2025, 06:32 UTC

Omandamised, ülevõtmised, äriostud

Sanofi Signs Deal for Sale of 50% Controlling Stake in Opella to CD&R

19. veebr 2025, 06:31 UTC

Omandamised, ülevõtmised, äriostud

Sanofi, CD&R Sign Opella Share Purchase Agreement

3. veebr 2025, 06:37 UTC

Omandamised, ülevõtmised, äriostud

Sanofi Says Transaction Is Part of Its Share Buyback Program

3. veebr 2025, 06:35 UTC

Omandamised, ülevõtmised, äriostud

L'Oreal: Sale Should Be Finalized in Coming Days

3. veebr 2025, 06:35 UTC

Omandamised, ülevõtmised, äriostud

L'Oreal: Transaction Will Optimize Balance Sheet, Diversify Financing Sources

3. veebr 2025, 06:34 UTC

Omandamised, ülevõtmised, äriostud

L'Oreal Says It Remains Important Sanofi Shareholder, Fully Supports Strategy

3. veebr 2025, 06:33 UTC

Omandamised, ülevõtmised, äriostud

L'Oreal Will Own 7.2% of Sanofi's Capital, 13.1% of Voting Rights After Transaction

3. veebr 2025, 06:32 UTC

Omandamised, ülevõtmised, äriostud

L'Oreal Selling 2.3% Stake in Sanofi for EUR101.50 a Share

3. veebr 2025, 06:31 UTC

Omandamised, ülevõtmised, äriostud

L'Oreal to Sell Sanofi Stake for EUR3B

3. veebr 2025, 06:31 UTC

Omandamised, ülevõtmised, äriostud

L'Oreal to Sell Sanofi Stake Back to Sanofi

30. jaan 2025, 10:47 UTC

Market Talk
Tulu

Sanofi's Buyback and Increased R&D Spending Are Positive -- Market Talk

30. jaan 2025, 10:31 UTC

Market Talk
Tulu

Sanofi's Lung Drug Beyfortus Sales Beat Stands Out Among 4Q Results -- Market Talk

30. jaan 2025, 06:32 UTC

Peamised uudised
Tulu

Sanofi Issues $5.2 Bln Share Buyback; Expects Sales, Core Earnings Growth

Võrdlus sarnastega

Hinnamuutus

Sanofi Prognoos

Hinnasiht

By TipRanks

16.75% tõus

12 kuu keskmine prognoos

Keskmine 64.75 USD  16.75%

Kõrge 67 USD

Madal 63 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Sanofi 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

3

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

54.84 / 58.29Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Strong Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.